TLR4 signaling in endothelial cells (ECs) induces vascular injury by disrupting the endothelial junctional barrier. However, it is not known whether TLR4 signaling can also promote endothelial barrier repair after vascular injury. Here we addressed the role of TAK1 activation downstream of TLR4 in the mechanism of vascular integrity. In inducible EC-restricted TAK1 knockout (TAK1 i∆EC ) mice, the endothelial barrier was compromised. Blocking TAK1 activity caused spontaneous loss of the endothelial barrier. Importantly, TAK1 inactivated GSK3β via AKT to prevent β-catenin downregulation. We observed in ECs of GSK3β i∆EC mice an increase in β-catenin transfer to the nucleus to form a complex with transcription factor FoxO1, thus repressing the expression of the tight junction protein claudin-5 and causing vascular leak.
Introduction
Endothelial barrier dysfunction results in protein-rich edema formation and inflammatory cell infiltration that characterize diseases such as acute respiratory distress syndrome (ARDS) (1, 2) . In the inflammatory context, endothelial barrier integrity is highly dependent on the processes governing endothelial barrier repair. VE-cadherin (VE-cad) forms Ca 2+ -dependent homophilic cis and trans dimers at adherens junctions (AJs) that establish cell-to-cell adhesion, which is essential for endothelial barrier integrity (3) (4) (5) . The cytoplasmic domain of VE-cad interacts with β-catenin (β-cat), which in turn interacts with the actin-associated protein α-catenin (3, 4) . The association between β-cat and VE-cad is essential for the formation of endothelial AJs (3, 4) . In septic patients and models of sepsis, the lungs are the first organ to fail because of the loss of endothelial barrier function (2) . In addition to AJs, the endothelial tight junctions (TJs) also play a critical role in endothelial barrier stability (5) (6) (7) (8) (9) (10) . Claudin-5 and occludin are the major TJ proteins in endothelial cells (5, 7) . Communication between AJs and TJs are thought to be essential for normal endothelial barrier integrity and stability (5, 6) . Phosphorylation of AJ protein VE-cad and its associated protein β-cat promotes loss of endothelial barrier integrity (11) (12) (13) (14) (15) (16) . Similar to AJs, phosphorylation of TJ proteins also causes endothelial barrier disruption (17, 18) . Despite both AJs and TJs being important for endothelial integrity, little is known about the signaling mechanisms that regulate endothelial barrier integrity through the control of the distinct set of proteins.
TAK1 is crucial in mediating inflammatory signals activated by cytokines and Toll-like receptor ligands (19) (20) (21) . TAK1 lies upstream of IκB kinase, p38 MAPK, JNK, and ERK, and causes the activation of NF-κB and MAPK signaling pathways (21, 22) . In B cells, TAK1 is required for B cell development and activation of NF-κB and MAPK signaling in response to TLR ligands, and BCR stimuli (23) (24) (25) ; whereas TAK1 in neutrophils negatively regulates NF-κB and p38MAP kinase activation (26) . A study using myeloid-specific TAK1 knockout mice showed that TAK1 restricts spontaneous NLRP3 inflammasome activation and thereby prevents cell death in macrophages (27) . TAK1 also suppresses RIPK1-dependent melanoma cell death (28) and RIPK3-dependent endothelial necroptosis (29) . Global as well as endothelial cell (EC)-specific TAK1 deletion in mice resulted in embryonic lethality (24, 30) . Inducible deletion of TAK1 in brain ECs suppressed interleukin 1β (IL-1β)-induced fever and lethargy (31) . Deletion of TAK1 in ECs in a tamoxifen-inducible manner in adult mice showed that endothelial TAK1 was essential in preventing TNF-a-induced endothelial cell apoptosis (32) . Here we investigated the role of TAK1 in regulating endothelial barrier integrity after vascular injury. We observed using inducible EC-restricted TAK1 knockout (TAK1 i∆EC ) mice that endothelial TAK1 was vital for maintaining endothelial barrier integrity and repair of the endothelial barrier after vascular injury. TAK1 functioned by preventing the activation of both GSK3b and FoxO1 via AKT. In TAK1 i∆EC mice, we observed a several-fold increase in expression of FoxO1. We also observed using GSK3β i∆EC a defective endothelial barrier secondary to β-cat upregulation. Thus, targeting the TAK1-AKT-GSK3b-FoxO1 axis is a potential therapeutic approach to treat the uncontrolled vascular leak in inflammatory diseases.
Results
Endothelial deletion of TAK1 disrupts the endothelial barrier and induces inflammation. Studies were made in tamoxifen-inducible EC-restricted TAK1 knockout (TAK1 iΔEC ) mice. TAK1 iΔEC mice were created by breeding loxP-flanked Map3k7 (TAK1 fl/fl ) mice (33) with inducible Cre-ER(T) driven by the 5'endothelial enhancer of stem cell leukemia locus (34) . TAK1 was not expressed in ECs of TAK1 iΔEC mice (Supplemental Fig. 1A-D) . Hematoxylin-and-eosin staining of lung sections from TAK1 iΔEC showed perivascular infiltration of inflammatory cells and hemorrhage as compared with tamoxifen treated TAK1 fl/fl mice (hereinafter referred to as TAK1 fl/fl or WT mice) ( Fig. 1A) . To determine whether EC-expressed TAK1 affects vascular barrier integrity, we assessed Evans blue albumin (EBA) tracer uptake in lung tissue. EBA uptake increased in TAK1 iΔEC mice compared with TAK1 fl/fl mice (Fig. 1B) . Pulmonary transvascular fluid filtration coefficient (Kf,c), a measure of endothelial permeability, increased 8-fold in TAK1 iΔEC lungs compared with WT (Fig. 1C) . EC-specific TAK1 deletion also increased mortality in response to LPS induced endotoxemia ( Fig. 1D) as well as polymicrobial sepsis induced by cecal ligation and puncture (CLP) as compared to control TAK1 fl/fl mice (Fig. 1E) .
To address whether the endothelial barrier disruption in TAK1 iΔEC mice is the result of endothelial death, we performed terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive staining. We did not observe TUNEL-positive cells in lungs of either TAK1 iΔEC or TAK1 fl/fl mice (Supplemental Figure 1E ). Knockdown of TAK1 in human lung microvascular ECs (ECs) using small interfering RNA (siRNA) also did not induce apoptosis (Supplemental Figure 1F ) indicating that TAK1 deficiency did not injure the endothelium due to apoptosis.
Inhibition of TAK1 activity disrupts endothelial barrier
Since TAK1 iΔEC mice showed increased endothelial permeability reflecting endothelial injury, we next determined whether TAK1 kinase activity was responsible for endothelial barrier disruption. On inhibiting TAK1 kinase activity with 5Z-7-oxozeaenol (OZ) (1 µM, 1 h), we observed marked reductions in the expression of VE-cad and b-catenin at AJs in ECs ( Fig. 1F) . Measurement of trans-endothelial resistance (TER) showed that OZ (1 µM) itself caused a time dependent decrease in TER ( Fig. 1G, 1H) indicating disassembly of endothelial AJs. We observed that the protease-activated receptor-1 (PAR-1) agonist thrombin (generated in vasculature during sepsis) produced a transient increase in permeability whereas LPS produced a sustained increase in permeability as reflected by the relative decreases in TER; however, both responses were more sustained and greater with OZ treatment as compared with controls ( Fig. 1G, 1H) . Next, to address the in vivo effect of TAK1 kinase inhibition, we measured PAR-1-induced changes in Kf,c in mouse lungs and observed that the PAR-1 agonist peptide (TFLLRNPNDK-NH2) induced a 3-fold increase in Kf,c over the basal value in WT mouse lungs ( Fig. 1I) , whereas in mouse lungs perfused with OZ (1 µM) for 30 min the PAR-1 agonist significantly augmented the increase in Kf,c (Fig. 1I) . WT mice, challenged with a low dose of LPS (5 mg/kg, i.p.,) for 6 h and then exposed to OZ as above, also showed a similar augmentation of increase in endothelial permeability (Fig. 1J) . These findings show that TAK1 kinase activity functions to suppress endothelial barrier injury in response to LPS and thrombin.
TAK1 inhibition of GSK3b prevents b-catenin degradation and maintains endothelial permeability
To examine mechanisms of TAK1 induced endothelial barrier protection, we focused on the expression of adherens junction protein b-catenin (b-cat) in TAK1 deficient ECs. Here we used ECs from TAK1 fl/fl.Cre+ mice that were treated with tamoxifen (2 µM) for 72 h to delete TAK1 ( Fig. 2A) , which reduced b-cat expression by 80% as compared with control ECs (Fig. 2B) . b-cat contains several consensus phosphorylation sites (amino acid positions: S29, S33, S37, T4, S45) for GSK3b (35) . GSK3b phosphorylation of b-cat promotes b-cat ubiquitination and degradation via the proteasomal pathway (35, 36) and inhibition of GSK3b has been linked to enhanced endothelial barrier function due to increased bcat expression at AJs (37) . Thus, we addressed whether TAK1 inhibited GSK3b and thereby stabilized bcat at AJs to promote barrier function. We first determined the effects of OZ, the inhibitor of TAK1 activity, on the phosphorylation of GSK3b on S9 to inactivate GSK3b in ECs (Fig. 2C, 2D ). OZ prevented basal as well as thrombin-and LPS-induced phosphorylation of GSK3b at S9 (Fig. 2C, 2D ). Furthermore, knockdown of TAK1 also prevented phosphorylation of GSK3b at S9 in ECs ( Fig. 2E ), suggesting that it would lead to increased phosphorylation of b-cat, increased b-cat degradation and hence decreased b-cat expression at AJs. To address whether this was the case, we determined the phosphorylation of S33, S37 and T41 on b-cat in control or OZ treated ECs (Fig. 2F, 2G ). We observed that thrombin and LPS both induced phosphorylation of b-cat in a time dependent manner in ECs ( Fig. 2F, 2G ) and that OZ increased b-cat phosphorylation at these sites ( Fig. 2F, 2G ). To address next whether the proteasomal pathway was responsible for b-cat degradation, we determined the effects of TAK1 inhibition on b-cat ubiquitination.
ECs were incubated for 2 h with the proteasomal inhibitor MG-132 and then challenged either with thrombin or LPS. We observed that basal as well as thrombin-and LPS-induced ubiquitination of b-cat was increased in OZ-treated ECs (Fig. 2H, 2I ). Since OZ treatment disrupted the endothelial barrier ( Fig.   1F-1J) , we determined the effect of the GSK3b inhibitor (SB216763) on OZ induced endothelial barrier disruption. Pretreatment with the GSK3b inhibitor prevented the OZ-induced loss of VE-cad and b-cat at AJs ( Fig. 2J) as well as OZ-plus thrombin-induced decreases in TER (Fig. 2K) . These results show that TAK1 inhibition of GSK3b prevents b-cat degradation and hence promotes b-cat localization at AJs and maintains endothelial permeability.
Endothelial-specific GSK3b deletion-dependent nuclear localization of β-catenin and FoxO1 increases endothelial permeability
Next, to examine the in vivo role of GSK3β in ECs and to determine its role in regulating endothelial permeability, we generated tamoxifen-inducible EC-restricted GSK3β knockout (GSK3β i∆EC ) mice (Supplemental Figure 2A-D) . We observed augmented β-cat expression in ECs from GSK3β i∆EC mice compared to WT littermates (GSK3β fl/fl ) ( Fig. 3A) , indicating that phosphorylation of b-cat and its degradation are reduced in the absence of GSK3β in ECs. We determined the effects of deletion of GSK3β on vascular permeability using GSK3β i∆EC . Basal as well as PAR-1-and LPS-induced increases in permeability were augmented in GSK3β i∆EC mice compared with WT mice (Fig. 3B, 3C ). In addition, polymicrobial sepsis induced by CLP produced 100% mortality in GSK3β i∆EC mice ( Fig. 3D) , whereas CLP induced only 20% mortality in GSK3β fl/fl mice ( Fig. 3D) . LPS dose of 10 mg/kg i.p. produced 100% mortality in GSK3β i∆EC mice ( Fig. 3E ) but the same challenge produced no mortality in GSK3β fl/fll mice ( Fig. 3E) .
To address possible alteration in overall b-cat expression in GSK3β i∆EC mice, we measured the subcellular distribution of b-cat. GSK3b depletion markedly reduced membrane associated b-cat expression at AJs whereas b-cat was diffusely localized in nuclei and cytoplasm ( Fig. 3F, 3G) .
Immunoblotting experiments showed that depletion of GSK3b induced a shift in the localization of b-cat from the cytosol to nuclear fraction as compared with control cells (Fig. 3F ). This was also seen with the transcription factor FoxO1 (Fig. 3F ) consistent with previous evidence (5, 6) . In the absence of GSK3b in ECs, anti-β-cat antibody immunoprecipitated both β-cat and FoxO1 as compared to ECs from WT mice ( Fig. 3H ).
FoxO1 inhibition restores the endothelial barrier in GSK3β i∆EC mice
To determine whether FoxO1/β-cat interaction in the nucleus is responsible for the loss of the endothelial barrier in GSK3β i∆EC mice, we analyzed the lung lysates from GSK3β fl/fl and GSK3β i∆EC mice. Under basal conditions, FoxO1 expression was increased in GSK3β i∆EC mice ( Fig. 4A) ; in contrast basal expression of claudin-5, occludin, and VE-cad were strikingly low in GSK3β i∆EC mice compared with basal levels in WT mice ( Fig. 4C, 4D ). However, β-cat expression was increased in GSK3β i∆EC mice compared with WT mice ( Fig. 4D) . Next, we studied the effect of FoxO1 inhibitor (AS1842856; it binds to the active site on FoxO1 to inhibit transcriptional activity of FoxO1 [38] ) on endothelial barrier stability in vivo. Here, we treated WT and GSK3β i∆EC mice with the FoxO1 inhibitor and then challenged them with LPS to assess endothelial barrier stability. In WT mice, LPS markedly reduced the expression of claudin-5, VE-cad, and β-cat ( Fig.   4C, 4D) . Interestingly, FoxO1 inhibitor treatment prevented LPS-induced loss of claudin-5, VE-cad, and β-cat expression in the lung (Fig. 4C, 4D ) as well as lung vascular leak as assessed by EBA uptake in WT mice ( Fig. 4E) . Similarly, we observed that in GSK3β i∆EC mice, FoxO1 inhibitor treatment restored the expression of claudin-5, occludin, VE-cad, and β-cat to normal levels ( Fig. 4C, 4D ) and prevented LPSinduced lung vascular leak ( Fig. 4E) . Thus, the mechanism of increased permeability seen following deletion of GSK3b and nuclear translocation of β-cat and β-cat/FoxO1 interaction involved reduced expression of adherens and tight junction proteins.
TAK1 activates AKT to suppress the function of GSK3β
Since we observed that chemical inhibition of TAK1 kinase blocked thrombin-or LPS-induced phosphorylation of GSK3β at S9, we addressed the possibility that TAK1 inactivates GSK3β through AKT, which is known to phosphorylate GSK3β at S9 to inactivate GSK3β (36) . In support of this concept, OZ treatment blocked thrombin-or LPS-induced phosphorylation of AKT ( Fig. 5A, 5B ). Further, thrombin or LPS stimulation caused interaction between TAK1 and AKT in ECs (Fig. 5C ). In addition, an AKT inhibitor prevented thrombin-or LPS-induced S-9 phosphorylation of GSK3b ( Fig. 5D, 5E) . Also, we observed that the AKT inhibitor blocked thrombin-or LPS-induced phosphorylation of AKT in ECs ( Fig.   5F, 5G) . In other experiments, we measured the effect of the AKT inhibitor on endothelial barrier function by measuring TER. We observed that AKT inhibition augmented basal as well as thrombin-or LPSinduced decrease in TER ( Fig. 5H, 5I ). Taken together, these results suggest that TAK1 activates AKT which in turn inactivates GSK3b in ECs.
TAK1 restricts FoxO1 function in ECs through AKT activation
Since AKT-mediated phosphorylation of FoxO1 inhibits FoxO1 DNA binding activity and expels FoxO1 the from nucleus (39-41), we investigated whether TAK1 occludes the function of FoxO1 via AKT.
We observed that TAK1 inhibitor OZ blocked both thrombin-and LPS-induced phosphorylation of FoxO1
at T-24 and S-256 in ECs ( Fig. 6A, 6B) . As a positive control, we showed that a FoxO1 inhibitor (AS1842856 [AS]) also blocked thrombin-or LPS-induced phosphorylation of FoxO1 in ECs ( Fig. 6A,   6B ). In addition, FoxO1 inhibition largely prevented the spontaneous loss of AJs in ECs ( Fig. 6C ) due to TAK1 inhibition. Moreover, concurrent inhibition of both GSK3b and FoxO1, completely reversed the OZ induced effect on endothelial AJs (Fig. 6C) as well as the LPS effect on endothelial barrier integrity as assessed by measuring TER (Fig. 6D, 6E) . These findings support the proposal that TAK1 controls the function of GSK3b and FoxO1 in ECs.
To define the in vivo role of EC-expressed TAK1 in regulating FoxO1, we analyzed lung lysates from TAK1 fl/fl and TAK1 iΔEC mice. Remarkably, we observed a several-fold increase in expression of FoxO1 ( Fig. 7A ) while the expression of AKT was suppressed in lungs of TAK1 iΔEC mice ( Fig. 7A) . Since FoxO1 represses the transcription of claudin-5 by associating with β-cat (6), we observed that claudin-5 expression was markedly reduced along with that of occludin, VE-cad, and β-cat in TAK1 iΔEC mice compared with TAK1 fl/fl mice (Fig. 7B, 7C) . LPS challenge caused downregulation of TJ and AJ proteins in both genotypes ( Fig. 7B, 7C) , however, the effect was more dramatic in TAK1 iΔEC mice ( Fig. 7B, 7C ). Next, we pretreated both genotypes with a FoxO1 inhibitor and then challenged with LPS and observed that FoxO1 inhibition prevented LPS-induced downregulation of TJ and AJ proteins ( Fig. 7B, 7C ) as well as lung vascular leak in both genotypes ( Fig. 7D) . To determine whether FoxO1 could be a potential therapeutic target to treat sepsis, we investigated the effect of FoxO1 inhibition on the survival of TAK1 fl/fl and TAK1 iΔEC mice after CLP. We administered the FoxO1 inhibitor or saline i.p. 6 h after CLP and monitored survival of both genotypes. In saline-treated TAK1 fl/fl mice, CLP produced 80% mortality in 4 days whereas in TAK1 iΔEC mice, CLP produced 100% mortality within 30 h ( Fig. 7E) . Importantly, we observed that FoxO1 inhibitor treatment markedly increased the survival of both TAK1 fl/fl and TAK1 iΔEC mice after CLP ( Fig. 7E) .
EC-specific FoxO1 deletion in mice attenuates sepsis-induced lung vascular leak and mortality
To further strengthen the role of TAK1 in regulating endothelial barrier function through FoxO1, we generated EC-restricted FoxO1 knockout (FoxO1 DEC ) mice. Here we used Cre-dependent Cas9 knockin mouse model (42) to generate FoxO1 DEC mice. First, we generated CRISPR/Cas9-cdh5-Cre mice and then, FoxO1 was deleted in adult mice ECs by liposome-mediated in vivo delivery of the plasmid (pGS) encoding single guide-RNA (sgRNA) to target mFoxO1. We used two different sgRNAs (FoxO1-sgRNA-1; FoxO1-sgRNA-2) to target the mFoxO1 or a scrambled sgRNA (Sc-sgRNA) as a control. We observed that administration of the plasmid encoding mFoxO1-sgRNA-1 effectively disrupted the expression of FoxO1 in lung ECs (Fig. 8A, 8B ). Sc-sgRNA or FoxO1-sgRNA-2 had no significant effect on FoxO1 expression.
LPS challenge had no effect on FoxO1 expression in FoxO1-sgRNA-1 (FoxO1 DEC ) mice whereas in WT (Sc-sgRNA-treated) mice, we observed increased expression of FoxO1 ( Fig. 8C) . Interestingly, LPS challenge caused downregulation of TJ and AJ proteins in WT mice ( Fig. 8D, 8E ), but LPS had no effect on the expression of TJ and AJ proteins in FoxO1 iΔEC mice ( Fig. 8D, 8E ). Consistent with these findings, we observed that LPS-induced lung vascular leak (Fig. 8F) , and polymicrobial sepsis-induced mortality ( Fig. 8G ) as markedly reduced in FoxO1 iΔEC mice. These findings collectively suggest that TAK1-mediated FoxO1 inhibition is crucial for endothelial barrier restoration after vascular injury. On the basis of these findings, we propose a model ( Fig. 8H) in which TAK1 inhibits the function of GSK3b and FoxO1 via AKT to regulate the endothelial barrier stability.
Discussion
In this study, we have uncovered the novel functions of TAK1 in regulating vascular homeostasis and repairing the endothelial barrier after vascular injury using our endothelial cell-restricted inducible TAK1 knockout (TAK1 iΔEC ) mouse. We observed that TAK1 iΔEC mice exhibited augmented basal lung vascular leak, and that PAR-1 or TLR-4 activation produced uncontrolled lung vascular leak in TAK1 iΔEC mice. Consistent with these results, blocking TAK1 kinase activity caused spontaneous loss of endothelial barrier function due to downregulation of β-cat at AJs in ECs. Importantly, we showed that TAK1 inactivates GSK3β by phosphorylating GSK3β on S9 via AKT activation to restore β-cat at AJs. To provide in vivo genetic evidence, we created EC-restricted inducible GSK3β knockout (GSK3β iΔEC ) mice and showed that increased β-cat expression in ECs of GSK3β iΔEC mice, supporting the role of GSK3β in regulating β-cat expression in ECs. Surprisingly, we observed that GSK3β deficiency in ECs induced the formation of β-cat/FoxO1 transcriptional complex, which in turn repressed the expression of the TJ protein claudin-5 to cause endothelial barrier destabilization. Further, we observed augmented expression of FoxO1 while the expression of the FoxO1 negative regulator AKT was suppressed in TAK1 iΔEC mice.
Strikingly, EC-restricted FoxO1 deletion of (FoxO1 DEC ) in mice suppressed sepsis-induced lung vascular leak and mortality. Thus, our results demonstrate for the first time that TAK1 functions as a rheostat in ECs to maintain and repair the endothelial barrier after vascular injury through ATK activation-mediated inhibition of GSK3β and FoxO1 in ECs.
We observed that either inhibition of TAK1 or deletion of TAK1 in ECs, induced loss of β-cat at AJs to cause endothelial barrier destabilization. In support these data, we observed augmented basal as well as thrombin-or LPS-induced phosphorylation and ubiquitination of β-cat in ECs with inhibited TAK1.
Consistent with the above findings, thrombin or LPS challenge failed to inactivate GSK3b in TAK1 inhibitor-treated ECs, supporting the concept that TAK1 is essential for GSK3b inhibition-mediated β-cat expression at AJs. Next, we investigated the link between TAK1 and GSK3b in ECs and showed that TAK1 interacts with and activates AKT in response to thrombin or LPS in ECs to phosphorylate S-9 on GSK3b thereby inhibiting GSK3b activity. In further experiments, we showed that, similar to TAK1 inhibition, AKT inhibition also induced loss of endothelial barrier function and augmented thrombin-or LPS-induced responses. Collectively, these results show that TAK1 regulates the endothelial barrier through AKT-dependent inhibition of GSK3b signaling in ECs.
GSK3b is known to participate in many cellular signaling pathways. It regulates the function of several transcription factors critical for inducing inflammation and cytokine production, including NF-kB, AP-1, CREB, NFAT, STAT proteins, and β-cat (43) (44) (45) (46) . However, GSK3b's in vivo role in ECs is poorly understood. To investigate the in vivo role of GSK3b in ECs, we generated tamoxifen inducible ECrestricted GSK3b knockout (GSK3β iΔEC ) mice, and unexpectedly we found that GSK3b deficiency in ECs prevented β-cat expression at AJs, which led to defective endothelial barrier function. Knockdown of GSK3b in HLMVECs also mimicked the phenotype of a defective endothelial barrier seen in GSK3β iΔEC mice. Although β-cat expression was increased in ECs of GSK3β iΔEC mice, the increased β-cat was primarily bound to transcription factor FoxO1 in the nucleus. Since the β-cat/FoxO1 complex is known to repress the expression of the TJ protein claudin-5 in ECs (5) , which induces a defective endothelial barrier (5) , we determined the expression of TJ proteins in GSK3β iΔEC mice and their wildtype counterparts.
Interestingly, we showed that expression of TJ proteins claudin-5 and occludin, and also AJ protein VEcad were markedly reduced under basal conditions in lungs of GSK3β iΔEC mice whereas β-cat was upregulated. Next, we observed that FoxO1 inhibitor treatment in vivo prevented LPS-induced loss of claudin-5, occludin, VE-cad, and β-cat in WT mice. Importantly, FoxO1 inhibitor treatment, restored the expression of these proteins to a normal level in GSK3β iΔEC mice and prevented LPS-induced lung vascular leak in both genotypes, thus supporting the hypothesis that the β-cat/FoxO1 complex in ECs causes vascular barrier instability.
FoxO1 expressed in ECs regulates vascular homeostasis (47) (48) (49) (50) (51) and its function is tightly regulated by the PI3K-AKT pathway (39) (40) (41) . AKT phosphorylation of FoxO1 at T-24 expels FoxO1 from nucleus whereas phosphorylation at S-256 inhibits FoxO1 binding to DNA, and thus AKT controls FoxO1 function.
The AKT isoform is probably AKT1, the main isoform in ECs that targets FoxO1 (52) . We used a pharmacological approach to examine whether TAK1 is required for AKT activation in response to inflammatory stimuli. We showed that TAK1 inhibition blocked both thrombin and LPS induced activation of AKT in ECs. Further, we showed that AKT inhibition blocked thrombin as well as LPS-induced phosphorylation (inactivation) of GSK3b in ECs. Also, we showed that AKT inhibition augmented the thrombin-or LPS-induced endothelial permeability response. These findings are in agreement with the previous report indicating increased vascular permeability in AKT1-null mice (53) .
Since we observed loss of endothelial barrier function in TAK1 iΔEC mice, we investigated whether endothelial TAK1 signaling is required for AKT activation during the endothelial repair process, and whether repair of the endothelial barrier involves AKT dependent inactivation of FoxO1 in ECs. We showed that chemical inhibition of TAK1 prevented AKT activation-mediated phosphorylation of FoxO1
at T-24 and S-256. Further, we showed that AKT activated downstream of PAR-1 or TLR4, phosphorylates FoxO1 in ECs. Consistent with these findings, we observed augmented expression of FoxO1 in TAK1 iΔEC mice whereas AKT expression was blocked. To address whether the loss of endothelial barrier function in TAK1 iΔEC mice was due to uncontrolled FoxO1 activation, we inhibited FoxO1 and measured sepsis-induced responses in WT and TAK1 iΔEC mice. We observed that FoxO1 inhibition prevented LPS-induced downregulation of TJ and AJ proteins and lung vascular leak in WT mice. Similarly, FoxO1 inhibition restored TJ and AJ proteins to the basal levels and prevented LPS-induced lung vascular leak in TAK1 iΔEC mice. Importantly, FoxO1 inhibition, markedly reduced CLP-induced mortality in both WT and TAK1 iΔEC mice. Further, we observed that in FoxO1 ΔEC mice, sepsis-induced lung vascular leak and mortality were substantially reduced. These findings collectively support the notion that TAK1 regulates endothelial barrier integrity through AKT-mediated inhibition of GSK3b and FoxO1 in ECs.
TAK1 has been shown to be crucial for mediating inflammation through NF-kB activation in many cell types (21) . Recent published studies have demonstrated that TAK1 is also essential to prevent cell death in macrophages, cancer cells, and ECs (27, 28, 32) . In our studies, under basal conditions we did not observe endothelial cell death either in TAK1 knockdown ECs or in TAK1-null ECs. We cannot rule out the possibility that during sepsis, TAK1-null ECs undergoes apoptosis to cause vascular barrier disruption.
Importantly, chemical inhibition of TAK1 caused spontaneous loss of endothelial barrier function indicating that constitutive activity of TAK1 could regulate endothelial barrier integrity by suppressing the function of GSK3b and FoxO1. Consistent with this notion, we observed that in TAK1 iΔEC mice, the sepsisinduced lung vascular injury response was not reversible, indicating that TAK1-mediated AKT activation during inflammation is critical for repairing the endothelial barrier after vascular injury. In conclusion, we have identified TAK1 as an upstream signaling molecule in ECs that controls the functions of GSK3b and FoxO1 to maintain and repair the endothelial barrier after vascular injury. We believe that this novel pathway controls the restoration rate of endothelial junctions under normal physiological conditions and in the setting of vascular leak. Thus, targeting the TAK1-AKT-GSK3b-FoxO1 axis is a potential therapeutic approach to treat the uncontrolled lung vascular leak seen in sepsis. Lung injury was assessed by pulmonary capillary filtration coefficient (Kf,c) measurement using isolated lung preparations (59) and in vivo Evans blue dye conjugated albumin (EBA) uptake in lungs (16, 57) . Ploymicrobial sepsis was induced by CLP as described (60) . Caecum was punctured using 18-gauze needle on 5 different places. For survival studies, mice were monitored four times daily.
Materials and methods

Cells and siRNA transfection:
HLMVECs were cultured in EGM-2MV supplemented with 15% FBS as described (16) . Mouse (C57BL/6) lung endothelial cells (ECs) were isolated and cultured as described previously (59) . Both cell types were used between passages 3 and 6. HLMVECs grown to 70-80% confluence on gelatin-coated culture dishes were transfected with target siRNAs or sc-siRNA as described (16) . At 72 h after transfection, cells were used for following experiments. Bone marrow-derived macrophages (BMDMs) from mice were generated by culture of bone marrow cells as described (61 Immunostaining: ECs grown on glass coverslips were washed with HBSS and fixed with 3% paraformaldehyde for 20 minutes. Cells were permeabilized with 0.1% Triton-X-100 for 15 min at 4°C.
Next, cells were blocked in 5% goat serum in HBSS for 1 h at room temperature, incubated with primary antibody overnight at 4°C followed by incubation with Alexa-Fluor-conjugated secondary antibody and 4',6-diamidino-2-phenylindole (DAPI) 1 h at room temperature. In each step, cells were washed three times with HBSS. Coverslips were mounted with prolong gold anti-fade reagent (Invitrogen) on glass slide. Lung tissue sections were immunostained as described (57) . Images were acquired with the Zeiss LSM 510 confocal microscope.
Immunoprecipitation and immunoblotting:
ECs grown to confluence treated with or without specific agents were three times washed with phosphatebuffered saline (PBS) at 4 0 C and lysed in lysis buffer (50 mM Tris-HCl, pH7.5, 150 mM NaCl, 1 mM EGTA, 1% Triton X-100, 0.25% sodium deoxycholate, 0.1% SDS, 10 μM orthovanadate, and proteaseinhibitor mixture as described (16) . Mouse lungs were homogenized in lysis buffer (16 
Transendothelial Electrical Resistance Measurement:
Real time changes in transendothelial monolayer electrical resistance (TER) was measured to assess endothelial barrier function (62) . Confluent endothelial monolayer incubated with 2% FBS containing medium was exposed to indicated inhibitors, thrombin, or LPS. Data are presented as resistance normalized to its starting value zero time.
Statistical Analysis: Immunoblot bands were quantified using NIH ImageJ software. ANOVA and Student's t-test (2-tailed), and log-rank test were used to determine statistical significance with a P value threshold set at <0.05. 
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